Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA...

|By:, SA News Editor

Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%.